Amanda Twellman-Dieppa is a 22 year old with NS Hodgkin's Lymphoma, stage 4b. She was diagnosed at 16, went through chemo and radiation and was in remission until she relapsed at 19 years old. She went through a grueling stem cell transplant and received a lifetime amount of radiation and once again went into remission until February 25, 2005. Her website is http://saveamanda.com/
She says: "After finding out that my cancer is back for the third time, my dad and I have been actively seeking a way for me to receive CD30, the most promising treatment for my type of cancer and in my eyes, my only hope. Since my diagnosis months ago, we have been devoting every effort and resource to get me this treatment, but to no avail. The pharmaceutical company, Medarex, produces CD30 and has been developing it over the past few years in clinical trials. It has been amazingly successful and has saved lives, but unfortunately I was diagnosed a few days after the clinical trials were temporarily closed to compile data. Although I could potentially receive CD30 under an emergency use clause, Medarex has refused to release this treatment that could save my life."
Visit her website to find out more or help.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...